首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Research And Treatment

Cancer Research And Treatment杂志,由Korean Cancer Association出版,于2001年创刊,4 issues/year,出版语言English,ISSN:1598-2998,E-ISSN:2005-9256。

投稿咨询
Cancer Research And Treatment
Cancer Research And Treatment
Cancer Research And Treatment
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
3区
影响因子
4.2
CiteScore
7.7
期刊收录
SCI、SCIE

Cancer Research And Treatment(中文译名:《癌症研究与治疗》),ISSN:1598-2998,EISSN:2005-9256,是Korean Cancer Association出版的国际性学术期刊,创刊于2001年,以4 issues/year形式稳定发行,2026年总发文量约107篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.2,2025年期刊CiteScore为7.7,2025年期刊自引率约2.4%,在中科院期刊分区体系中位列医学大类3区,在所属学科领域具备高学术影响力与国际认可度。Cancer Research And Treatment长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期>12周,或约稿,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,South KoreaCHINA MAINLAND、USA、Japan、Taiwan、Italy、Spain等为核心发文国家与地区;SEOUL NATIONAL UNIVERSITY (SNU)SUNGKYUNKWAN UNIVERSITY (SKKU)、NATIONAL CANCER CENTER - KOREA (NCC)、YONSEI UNIVERSITY、UNIVERSITY OF ULSAN、CATHOLIC UNIVERSITY OF KOREA、KOREA UNIVERSITY等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
3区
ONCOLOGY 肿瘤学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 108 / 333

67.7

学科:ONCOLOGY SCIE Q2 93 / 333

72.22

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 91 / 322

71.9

学科:ONCOLOGY SCIE Q1 69 / 322

78.73


中国学者近期发文

1
Elevated SLC3A2 Expression Promotes the Progression of Gliomas and Enhances Ferroptosis Resistance through the AKT/NRF2/GPX4 Axi

Author:Zheng, Yuqian; Zhou, Shaolong; Tao, Yiran; Shi, Zimin; Li, Xiang; Fu, Xudong; Ma, Jian; Hu, Weihua; Liang, Wulong; Wang, Xinjun

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. -. DOI: 10.4143/crt.2024.933

2
Adjuvant Chemotherapy in Breast Cancer after Neoadjuvant Therapy: Essential or Optional

Author:Zhang, Di; Yang, Luo; Zheng, Yuan; Zhou, Qi

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. 208-220. DOI: 10.4143/crt.2024.1254

3
The Role of Circulating Tumor Cell as a Promising Biomarker in the Evaluation of Pulmonary Nodules: A Prospective Stud

Author:Wang, Shijie; Xu, Changdan; Xu, Xiaohong; Shao, Weipeng; Wang, Guohui; Yang, Xiongtao; Gao, Liwei; Teng, Feng; Sun, Hongliang; Zhao, Yue; Feng, Hongxiang; Zhu, Guangying

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. 128-140. DOI: 10.4143/crt.2024.841

4
Deciphering the Risk of Developing Lung Cancer after the Diagnosis of Gastric Cancer with Genetic Evidence: A European and East Asian Populations-Based Mendelian Randomization Analysi

Author:Chen, Jiansheng; Zeng, Aiming; Yu, Yunzhe; Sun, Sida; Liao, Liqun; Huang, Siwei; Yang, Zhongshan; Zhou, Junfeng; Wu, Weijie

Journal: CANCER RESEARCH AND TREATMENT. 2026; Vol. 58, Issue 1, pp. 242-251. DOI: 10.4143/crt.2024.875

5
Synergistic Activation of LEPR and ADRB2 Induced by Leptin Enhances Reactive Oxygen Specie Generation in Triple-Negative Breast Cancer Cell

Author:Liu, Chang; Yu, Jing; Du, Yongjun; Xie, Yu; Song, Xiaofei; Yan, Yan; Wang, Yue; Qin, Junfang

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 2, pp. 457-477. DOI: 10.4143/crt.2024.368

6
Combination Therapy of Pyrotinib and Metronomic Vinorelbine in HER2+Advanced Breast Cancer after Trastuzumab Failure (PROVE): A Prospective Phase 2 Stud

Author:Hao, Chunfang; Wang, Xu; Shi, Yehui; Tong, Zhongsheng; Li, Shufen; Liu, Xiaodong; Zhang, Lan; Zhang, Jie; Meng, Wenjing; Zhang, Li

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 2, pp. 434-442. DOI: 10.4143/crt.2024.340

7
The Oncogenic Role of TNFRSF12A in Colorectal Cancer and Pan-Cancer Bioinformatics Analysi

Author:Wang, Chuyue; Zhao, Yingying; Chen, You; Shi, Ying; Yang, Zhiying; Wu, Weili; Ma, Rui; Wang, Bo; Sun, Yifeng; Yuan, Ping

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 1, pp. 212-228. DOI: 10.4143/crt.2024.408

8
Integrated Transcriptomic Landscape and Deep Learning Based Survival Prediction in Uterine Sarcoma

Author:Song, Yaolin; Li, Guangqi; Zhang, Zhenqi; Liu, Yinbo; Jia, Huiqing; Zhang, Chao; Wang, Jigang; Hu, Yanjiao; Hao, Fengyun; Liu, Xianglan; Xie, Yunxia; Ma, Ding; Li, Ganghua; Tai, Zaixian; Xing, Xiaoming

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 1, pp. 250-266. DOI: 10.4143/crt.2024.343

9
A Single-Arm Phase II Clinical Trial of Fulvestrant Combined with Neoadjuvant Chemotherapy of ER+/HER2-Locally Advanced Breast Cancer: Integrated Analysis of 18F-FES PET-CT and Metabolites with Treatment Respons

Author:Shao, Qing; Zhang, Ningning; Pan, Xianjun; Zhou, Wenqi; Wang, Yali; Chen, Xiaoliang; Wu, Jing; Zeng, Xiaohua

Journal: CANCER RESEARCH AND TREATMENT. 2025; Vol. 57, Issue 1, pp. 126-139. DOI: 10.4143/crt.2023.1251


在线咨询

Cancer Research And Treatment

国际简称:CANCER RES TREAT参考译名:癌症研究与治疗

年发文量:107 CiteScore:7.7 是否预警:否 Gold OA文章占比:99.43% 研究类文章占比:97.20%

杂志社联系方式:RM 1824, GWANGHWAMUN OFFICIA, 92 SAEMUNAN-RO, JONGNO-GU, SEOUL, SOUTH KOREA, 110-999

Cancer Research And Treatment